Chemocentryx Stock Story


USD 50.89  0.37  0.73%   

While some millenniums are indifferent towards healthcare space, it makes sense to concentrate on Chemocentryx. We will analyze why Chemocentryx investors may still consider a stake in the business. Is the entity valuation justified? I am going to cover the stock perspective on valuation to give you a better outlook on taking a position in it.
Published over two months ago
View all stories for Chemocentryx | View All Stories

Ready to invest in Chemocentryx now and quit it next quarter?

Chemocentryx currently holds 73.28 M in liabilities with Debt to Equity (D/E) ratio of 0.26, which may suggest Chemocentryx is not taking enough advantage from borrowing.
Our investment recommendation module complements current analysts and expert consensus on Chemocentryx. It analyzes the firm potential to grow using all fundamental, technical, and market related data available at the time.
We determine the current worth of Chemocentryx using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Chemocentryx based exclusively on its fundamental and basic technical indicators. By analyzing Chemocentryx's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Chemocentryx's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Chemocentryx. We calculate exposure to Chemocentryx's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Chemocentryx's related companies.

Chemocentryx Investment Alerts

Chemocentryx investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Chemocentryx performance across your portfolios.Please check all investment alerts for Chemocentryx

Chemocentryx Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Chemocentryx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Chemocentryx competition to find correlations between indicators driving the intrinsic value of Chemocentryx.

How does Chemocentryx utilize its cash?

To perform a cash flow analysis of Chemocentryx, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Chemocentryx is receiving and how much cash it distributes out in a given period. The Chemocentryx cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Chemocentryx Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (75.62 Million)

Acquisition by Herron Jennifer Lyn of 17237 shares of Chemocentryx subject to Rule 16b-3

Legal trades by Chemocentryx insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Chemocentryx insider trading alert for grant of common stock by Herron Jennifer Lyn, the corporate stakeholder, on 30th of June 2022. This event was filed by Chemocentryx Inc with SEC on 2022-06-30. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.


This firm reported the previous year's revenue of 32.22 M. Net Loss for the year was (131.75 M) with loss before overhead, payroll, taxes, and interest of (51.07 M).

Margins Breakdown

Chemocentryx profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Chemocentryx itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Chemocentryx profit margins.
Operating Margin(100.36)
EBITDA Margin(4.16)
Gross Margin0.94
Profit Margin(4.41)

Chemocentryx Net Income Per Employee is nearly stable at the moment. Chemocentryx Revenue Per Employee is nearly stable at the moment. Additionally, Chemocentryx Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years. Chemocentryx Net Income Per Employee is nearly stable at the moment. Chemocentryx Revenue Per Employee is increasing over the last 8 years. Additionally, Chemocentryx Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years.

Over 3 percent rise for Chemocentryx. What does it mean for stockholders?

Current mean deviation is at 4.04. Chemocentryx exhibits very low volatility with skewness of 0.16 and kurtosis of 1.64. However, we advise investors to further study Chemocentryx technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Chemocentryx's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Chemocentryx's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Chemocentryx Implied Volatility

Chemocentryx's implied volatility exposes the market's sentiment of Chemocentryx stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Chemocentryx's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Chemocentryx stock will not fluctuate a lot when Chemocentryx's options are near their expiration.

Our Bottom Line On Chemocentryx

While other entities in the biotechnology industry are either recovering or due for a correction, Chemocentryx may not be as strong as the others in terms of longer-term growth potentials. To conclude, as of the 30th of May 2022, we believe that at this point, Chemocentryx is undervalued with below average chance of financial distress within the next 2 years. Our actual 'Buy-vs-Sell' recommendation on the company is Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Chemocentryx. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to